MedTrace Logo

A Clinical Study of Adebrelimab in Combination With SHR-8068 and Chemoradiotherapy as Perioperative Therapy for Locally Advanced Rectal Cancer

NCT07454720 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 165

Last updated 2026-05-05

No results posted yet for this study

Summary

The study is being conducted to evaluate the safety and efficacy of Adebrelimab and SHR-8068 in combination with chemoradiotherapy in subjects with rectal cancer.

Conditions

  • Locally Advanced Resectable Rectal Cancer

Interventions

DRUG

Chemotherapy

Chemotherapy.

DRUG

Adebrelimab combined with chemotherapy

Adebrelimab combined with chemotherapy.

DRUG

Adebrelimab in combination with SHR-8068 and chemotherapy

Adebrelimab in combination with SHR-8068 and chemotherapy.

Sponsors & Collaborators

  • Suzhou Suncadia Biopharmaceuticals Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-23
Primary Completion
2032-11-30
Completion
2035-11-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07454720 on ClinicalTrials.gov